Loading...
Please wait, while we are loading the content...
Similar Documents
High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Ponce, Doris M. Hilden, Patrick Mumaw, Christen L. Vincent, Marta González Lubin, Marissa N. Giralt, Sergio A. Goldberg, Jenna Elyse Hanash, Alan M. Hsu, Katharine C. Jenq, Robert R. Perales, M. Gámez Sauter, Craig S. Brink, Marcel R. M. Van Den Young, James W. Brentjens, Renier J. Kernan, Nancy A. Prockop, Susan E. O'reilly, Richard J. Scaradavou, Andromachi Paczesny, Sophie Barker, Juliet |
| Copyright Year | 2015 |
| Abstract | While cord blood transplantation (CBT) is an effective therapy for hematologic malignancies, acute graft-versus-host disease (aGVHD) is a leading cause of transplant-related mortality (TRM). We investigated if biomarkers could predict aGVHD and TRM after day 28 in CBT recipients. Day 28 samples from 113 CBT patients were analyzed. Suppressor of tumorigenicity 2 (ST2) was the only biomarker associated with grades II-IV and III-IV aGVHD and TRM. Day 180 grade III-IV aGVHD in patients with high ST2 levels was 30% (95% confidence interval [CI], 18-43) vs 13% (95% CI, 5-23) in patients with low levels (P = .024). The adverse effect of elevated ST2 was independent of HLA match. Moreover, high day 28 ST2 levels were associated with increased TRM with day 180 estimates of 23% (95% CI, 13-35) vs 5% (95% CI, 1-13) if levels were low (P = .001). GVHD was the most common cause of death in high ST2 patients. High concentrations of tumor necrosis factor receptor-1, interleukin-8, and regenerating islet-derived protein 3-α were also associated with TRM. Our results are consistent with those of adult donor allografts and warrant further prospective evaluation to facilitate future therapeutic intervention to ameliorate severe aGVHD and further improve survival after CBT. |
| Starting Page | 199 |
| Ending Page | 205 |
| Page Count | 7 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://www.bloodjournal.org/content/bloodjournal/early/2014/11/05/blood-2014-06-584789.full.pdf?sso-checked=true |
| Alternate Webpage(s) | http://www.bloodjournal.org/content/bloodjournal/125/1/199.full.pdf?sso-checked=true |
| PubMed reference number | 25377785v1 |
| Alternate Webpage(s) | https://doi.org/10.1182/blood-2014-06-584789 |
| DOI | 10.1182/blood-2014-06-584789 |
| Journal | Blood |
| Volume Number | 125 |
| Issue Number | 1 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Acute GVH disease Allograft surgical material Biological Markers Cessation of life Confidence Intervals Estimated Grade Graft versus host disease prophylaxis/therapy Hematologic Neoplasms Hematological Disease Hematology (discipline) Patients ST2 gene Transplant-Related Mortality Transplanted tissue Tumor Necrosis Factor Receptor Tumorigenicity umbilical cord blood transplantation |
| Content Type | Text |
| Resource Type | Article |
